US · Healthcare · Biotechnology
EPS came in at -1.17 against a street estimate of -1.20 — a beat of 2.5%.
Analysts rate Xenon Pharmaceuticals Inc a strong buy (19 buy, 0 hold, 0 sell out of 19) with an average price target of $80.93.
| Fund | Stake |
|---|---|
| FMR Inc | 11.19% |
| venBio Select Advisor LLC | 5.98% |
| BlackRock Inc | 5.83% |
| Wellington Management Company LLP | 5.00% |
| Driehaus Capital Management LLC | 4.65% |
| Polar Capital Holdings PLC | 4.56% |
| HHG PLC | 4.32% |
| Capital Research & Mgmt Co - Division 3 | 2.77% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-06-03 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-22 |
| Board / officer change · Q2 2026 | 2026-04-13 |
| Company announcement · Q1 2026 | 2026-03-13 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Xenon Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.